Gilead Sciences: Arthritis, Rheumatoid trials

The registry lists 12 Arthritis, Rheumatoid studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 6Phase 2 3Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy ParticipantsCompletedNCT04608344Phase 1Results posted
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic FunctionCompletedNCT03417778Phase 1Results posted
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedNCT02889796Phase 3Results posted
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyCompletedNCT02886728Phase 3Results posted
• Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateCompletedNCT02885181Phase 2Results posted
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentCompletedNCT02873936Phase 3Results posted
• Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisTerminatedNCT02862574Phase 2Results posted
• Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)CompletedNCT02626026Phase 1Results posted
• Study of GS-0151 in Participants With Rheumatoid ArthritisActive, not recruitingNCT06902519Phase 1
• Study of GS-0272 in Participants With Rheumatoid ArthritisTerminatedNCT06031415Phase 1
• Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) TreatmentWithdrawnNCT05165771Phase 2
• Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid ArthritisCompletedNCT02176876Phase 1